Penicillium nalgiovense Laxa isolated from Antarctica is a new source of the antifungal metabolite amphotericin B
Abstract Background The need for new antibiotic drugs increases as pathogenic microorganisms continue to develop resistance against current antibiotics. We obtained samples from Antarctica as part of a search for new antimicrobial metabolites derived from filamentous fungi. This terrestrial environm...
Main Authors: | , , , , |
---|---|
Format: | Other/Unknown Material |
Language: | English |
Published: |
BioMed Central Ltd.
2015
|
Subjects: | |
Online Access: | http://www.fungalbiolbiotechnol.com/content/2/1/1 |
id |
ftbiomed:oai:biomedcentral.com:s40694-014-0011-x |
---|---|
record_format |
openpolar |
spelling |
ftbiomed:oai:biomedcentral.com:s40694-014-0011-x 2023-05-15T13:49:09+02:00 Penicillium nalgiovense Laxa isolated from Antarctica is a new source of the antifungal metabolite amphotericin B Svahn, K Chryssanthou, Erja Olsen, Björn Bohlin, Lars Göransson, Ulf 2015-01-17 http://www.fungalbiolbiotechnol.com/content/2/1/1 en eng BioMed Central Ltd. http://www.fungalbiolbiotechnol.com/content/2/1/1 Copyright 2015 Svahn et al.; licensee BioMed Central. Amphotericin B Penicillium nalgiovense Laxa Antarctica Research 2015 ftbiomed 2015-01-25T00:50:04Z Abstract Background The need for new antibiotic drugs increases as pathogenic microorganisms continue to develop resistance against current antibiotics. We obtained samples from Antarctica as part of a search for new antimicrobial metabolites derived from filamentous fungi. This terrestrial environment near the South Pole is hostile and extreme due to a sparsely populated food web, low temperatures, and insufficient liquid water availability. We hypothesize that this environment could cause the development of fungal defense or survival mechanisms not found elsewhere. Results We isolated a strain of Penicillium nalgiovense Laxa from a soil sample obtained from an abandoned penguin’s nest. Amphotericin B was the only metabolite secreted from Penicillium nalgiovense Laxa with noticeable antimicrobial activity, with minimum inhibitory concentration of 0.125 μg/mL against Candida albicans . This is the first time that amphotericin B has been isolated from an organism other than the bacterium Streptomyces nodosus . In terms of amphotericin B production, cultures on solid medium proved to be a more reliable and favorable choice compared to liquid medium. Conclusions These results encourage further investigation of the many unexplored sampling sites characterized by extreme conditions, and confirm filamentous fungi as potential sources of metabolites with antimicrobial activity. Other/Unknown Material Antarc* Antarctica South pole South pole BioMed Central South Pole Laxa ENVELOPE(-17.055,-17.055,65.344,65.344) |
institution |
Open Polar |
collection |
BioMed Central |
op_collection_id |
ftbiomed |
language |
English |
topic |
Amphotericin B Penicillium nalgiovense Laxa Antarctica |
spellingShingle |
Amphotericin B Penicillium nalgiovense Laxa Antarctica Svahn, K Chryssanthou, Erja Olsen, Björn Bohlin, Lars Göransson, Ulf Penicillium nalgiovense Laxa isolated from Antarctica is a new source of the antifungal metabolite amphotericin B |
topic_facet |
Amphotericin B Penicillium nalgiovense Laxa Antarctica |
description |
Abstract Background The need for new antibiotic drugs increases as pathogenic microorganisms continue to develop resistance against current antibiotics. We obtained samples from Antarctica as part of a search for new antimicrobial metabolites derived from filamentous fungi. This terrestrial environment near the South Pole is hostile and extreme due to a sparsely populated food web, low temperatures, and insufficient liquid water availability. We hypothesize that this environment could cause the development of fungal defense or survival mechanisms not found elsewhere. Results We isolated a strain of Penicillium nalgiovense Laxa from a soil sample obtained from an abandoned penguin’s nest. Amphotericin B was the only metabolite secreted from Penicillium nalgiovense Laxa with noticeable antimicrobial activity, with minimum inhibitory concentration of 0.125 μg/mL against Candida albicans . This is the first time that amphotericin B has been isolated from an organism other than the bacterium Streptomyces nodosus . In terms of amphotericin B production, cultures on solid medium proved to be a more reliable and favorable choice compared to liquid medium. Conclusions These results encourage further investigation of the many unexplored sampling sites characterized by extreme conditions, and confirm filamentous fungi as potential sources of metabolites with antimicrobial activity. |
format |
Other/Unknown Material |
author |
Svahn, K Chryssanthou, Erja Olsen, Björn Bohlin, Lars Göransson, Ulf |
author_facet |
Svahn, K Chryssanthou, Erja Olsen, Björn Bohlin, Lars Göransson, Ulf |
author_sort |
Svahn, K |
title |
Penicillium nalgiovense Laxa isolated from Antarctica is a new source of the antifungal metabolite amphotericin B |
title_short |
Penicillium nalgiovense Laxa isolated from Antarctica is a new source of the antifungal metabolite amphotericin B |
title_full |
Penicillium nalgiovense Laxa isolated from Antarctica is a new source of the antifungal metabolite amphotericin B |
title_fullStr |
Penicillium nalgiovense Laxa isolated from Antarctica is a new source of the antifungal metabolite amphotericin B |
title_full_unstemmed |
Penicillium nalgiovense Laxa isolated from Antarctica is a new source of the antifungal metabolite amphotericin B |
title_sort |
penicillium nalgiovense laxa isolated from antarctica is a new source of the antifungal metabolite amphotericin b |
publisher |
BioMed Central Ltd. |
publishDate |
2015 |
url |
http://www.fungalbiolbiotechnol.com/content/2/1/1 |
long_lat |
ENVELOPE(-17.055,-17.055,65.344,65.344) |
geographic |
South Pole Laxa |
geographic_facet |
South Pole Laxa |
genre |
Antarc* Antarctica South pole South pole |
genre_facet |
Antarc* Antarctica South pole South pole |
op_relation |
http://www.fungalbiolbiotechnol.com/content/2/1/1 |
op_rights |
Copyright 2015 Svahn et al.; licensee BioMed Central. |
_version_ |
1766250914345123840 |